SQLite Web: event

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-16T18:53:43.260650+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:c96e3d5ebd0740c4","evidence_event_ids":["evt_fa9686a8ca00"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/should-you-forget-cvs-health-and-invest-purer-healthcare-play","as_of":"2026-04-16T18:53:43.260650+00:00","canonical_url":"https://www.fool.com/investing/2026/04/16/should-you-forget-cvs-health-and-invest-in-a-purer/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/should-you-forget-cvs-health-and-invest-purer-healthcare-play","article_chars":4857,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_dee1a655bf2c0bc7","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/16/should-you-forget-cvs-health-and-invest-in-a-purer/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-17T02:10:08.837506+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsCVS Health has a far more diversified business than Novo Nordisk.","fetched_title":"Should You Forget CVS Health and Invest in a Purer Healthcare Play? | Nasdaq","final_url":"https://www.nasdaq.com/articles/should-you-forget-cvs-health-and-invest-purer-healthcare-play","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/should-you-forget-cvs-health-and-invest-purer-healthcare-play","source_event_id":"evt_fa9686a8ca00","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"136b8ba849e56698","kind":"unusual_volume","published_at":"2026-04-16T18:20:00+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["December 17, 2004","April 15, 2005","April 16, 2026"],"entities":[{"asset_class":"equity","name":"CVS Health","relevance":"high","symbol":"CVS","type":"company"},{"asset_class":"equity","name":"Novo Nordisk","relevance":"high","symbol":"NVO","type":"company"},{"asset_class":"equity","name":"Eli Lilly","relevance":"medium","symbol":"LLY","type":"company"}],"event_type":"other","information_gaps":["Unusual volume delta details are missing: no baseline volume, no current volume, no volume ratio vs average, and no direction (e.g., above/below average) are provided in the text.","No explicit confirmation is given that any volume change is driven by news; the article is a general investment comparison rather than a trading/volume event report.","No specific catalyst tied to unusual volume is stated; the article discusses business diversification and long-term outlook rather than near-term trading triggers."],"key_facts":["CVS Health is described as being best known for its pharmacy chain but also having a diversified healthcare business.","The article states CVS Health is one of the largest U.S. health insurers via Aetna and has a pharmacy benefits manager presence.","The article says CVS Health has boosted its presence in primary care and owns a subsidiary seeking to partner with biosimilar drugmakers to bring cheaper medicines to market.","The article argues diversification can have disadvantages, such as spreading resources thin and potentially leading to less-than-optimal capital allocation and lower growth.","Novo Nordisk is described as a drugmaker focused on metabolic diseases and generating almost all revenue from that area.","The article states Novo Nordisk has been a leader in diabetes drugs and a top player in weight management.","The article says Novo Nordisk lost ground in the weight loss market to Eli Lilly.","The article attributes recent stock weakness to clinical setbacks in Novo Nordisk\u2019s core area.","The article claims diversified healthcare companies may navigate challenges in one area while still performing relatively well.","The article states CVS Health is considered attractive to buy right now by the author, citing diversification and a vertically integrated model.","The article states Novo Nordisk\u2019s stock has declined significantly over the past two years but could bounce back as clinical programs advance over the next few years."],"numeric_claims":[],"primary_claim":"CVS Health is described as having a far more diversified healthcare business than Novo Nordisk, and both companies are presented as attractive for long-term investors.","relevance_score":0.25,"sentiment":"mixed","source_quality":"high","summary":"The article compares CVS Health (a diversified healthcare company) with Novo Nordisk (a more focused drugmaker) and argues both could be attractive long-term investments. It does not provide any unusual trading volume data or a specific volume-ratio signal.","topics":["equities","healthcare sector","company comparison","long-term investing","diversification vs focus","pharmacy benefits management","primary care","biosimilars","GLP-1/weight management","clinical setbacks"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsCVS Health has a far more diversified business than Novo Nordisk.","tickers":[],"title":"Should You Forget CVS Health and Invest in a Purer Healthcare Play?","url":"https://www.fool.com/investing/2026/04/16/should-you-forget-cvs-health-and-invest-in-a-purer/"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

event_store.db — events

Update row 61446 in events